Novel (<i>E</i>)‐3‐(3‐Oxo‐4‐substituted‐3,4‐dihydro‐2<i>H</i>‐benzo[<i>b</i>][1,4]oxazin‐6‐yl)‐<i>N</i>‐hydroxypropenamides as Histone Deacetylase Inhibitors: Design, Synthesis and Bioevaluation
作者:Doan Minh Sang、Ik Ho Na、Duong Tien Anh、Do Thi Mai Dung、Nguyen Thi Thu Hang、Nguyen T. Phuong‐Anh、Pham‐The Hai、Dao Thi Kim Oanh、Truong Thanh Tung、Soo Jung Lee、Joo Hee Kwon、Jong Soon Kang、Sang‐Bae Han、Dinh Thi Thanh Hai、Nguyen‐Hai Nam
DOI:10.1002/cbdv.202201030
日期:2023.5
Herein, we report the design, synthesis and evaluation of novel (E)-3-(3-oxo-4-substituted-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl)-N-hydroxypropenamides (4 a–i, 7 a–g) targeting histone deacetylases. Three human cancer cell lines were used to test the cytotoxicity of the synthesized compounds (SW620, colon; PC-3, prostate; NCI−H23, lung cancer); inhibitory activity towards HDAC; anticancer activity;
在此,我们报告了新型 ( E )-3-(3-oxo-4-substituted-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl) 的设计、合成和评估- N -hydroxypropenamides ( 4 a – i , 7 a – g ) 靶向组蛋白脱乙酰酶。三种人类癌细胞系用于测试合成化合物的细胞毒性(SW620,结肠;PC-3,前列腺;NCI-H23,肺癌);对 HDAC 的抑制活性;抗癌活性;以及它们对细胞周期和细胞凋亡的影响。因此,带有烷基取代基的化合物4 a – i似乎不如含苄基化合物7 a – g有效在所有生物测定中。化合物7 e – f被发现是最活跃的 HDAC 抑制剂,IC 50分别为 1.498±0.020 μM 和 1.794±0.159 μM。在细胞毒性和抗癌试验方面,7e和7f也显示出良好的活性,IC 50值在微摩尔范围内。此外,化合物7f对